SciClone Granted Development And Commercial Rights For Telavancin In China

(RTTNews) - Theravance Biopharma, Inc. (TBPH), through an affiliate, and SciClone Pharmaceuticals (SCLN), a U.S.-based, China-focused specialty pharmaceutical company, announced they have entered into a development and commercialization agreement granting SciClone exclusive development and commercial rights for the antibiotic VIBATIV (telavancin) in China and certain adjacent territories. In exchange, Theravance Biopharma will be eligible to receive upfront and regulatory milestone payments totaling $6 million.

The companies plan to pursue development and commercialization of VIBATIV in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Additional indications may include complicated skin and skin structure infections, and potentially bacteremia.